Serotonin 5-HT(1A) receptor agonists as antidepressants: Pharmacological rationale and evidence for efficacy

CNS Drugs

Volumn 10, Issue 5, 1998, Pages 343-353

  Heiser, Jon F ^a   Wilcox, Charles S ^a  

^a Pharmacology Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; FLESINOXAN; IPSAPIRONE; SEROTONIN 1A AGONIST; TANDOSPIRONE; ZALOSPIRONE;

DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031785156     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810050-00004     Document Type: Review

References (43)

1. 1A agonists: a comparative review. CNS Drugs 1994 Sep; 2: 234-51
2. Schweitzer I, Tuckwell V, Johnson G. A review of the use of augmentation therapy for the treatment of resistant depression: implications for the clinician. Aust NZ J Psychiatry 1997 Jun; 31 (3): 340-52
3. Borne RF. Serotonin: the neurotransmitter for the 90's. Drug Topics 1994 Oct; 138 (19): 108-17
4. Fulton B, Brogden RN. Buspirone: an updated review of its clinical pharmacology and therapeutic applications. CNS Drugs 1997 Jan; 7 (1): 68-88
5. Dubovsky SL. Approaches to developing new anxiolytics and antidepressants. J Clin Psychiatry 1993 May; 5 Suppl. 54: 75-83
6. Eison MS. Azapirones: mechanism of action in anxiety and depression. Drug Ther 1990 Aug; 20 Suppl.: 3-8
7. Keichel JR, Gammans RE. Pharmacocinétique de la buspirone. Psychol Med 1989; 21: 19-31
8. Cohn JB, Wilcox CS. Buspirone: effectiveness, safety and mechanisms of action. IM - Internal Medicine for the Specialist 1987 Jan; 8 (1): 216-24
9. 2-adrenoceptor antagonist activity may account for the effects of buspirone in an anti-conflict test in the rat. Eur J Pharmacol 1988; 155: 129-37
10. 1A receptors in anxiety. In: Briley M, File SE, editors. New concepts in anxiety. London: Macmillan Press, 1991: 94-129
11. McIvor RJ, Sinanan K. Buspirone-induced mania [letter]. Br J Psychiatry 1991 Jan; 158: 136-7
12. Feighner JP, Boyer WF. Buspirone in the treatment of depression. Drug Ther 1990 Aug; 20 Suppl.: 9-17
13. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990 Jun; 10 Suppl. 3: 67S-76S
14. Cohn JB, Wilcox CS, Bowden CL, et al. Double-blind comparison of buspirone and clorazepate in anxious outpatients with and without depressive symptoms. Psychopathology 1992; Suppl. 1: 10-21
15. Tollefson GD, Lancaster SP, Montague-Clouse J. The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacol Bull 1991; 27 (2): 163-70
16. Gammans RE, Stringfellow JC, Hvizdos AJ, et al. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms: a meta-analysis of eight randomized, controlled studies. Neuropsychobiology 1992; 25 (4): 193-201
17. Schweizer E, Rickels K, Hassman H. A double-blind, placebo-controlled comparison of imipramine and buspirone in the treatment of major depression in the elderly in the community [abstract]. Psychopharmacol Bull 1994; 30 (4): 639
18. Jenkins SW, Robinson DS, Fabre LF, et al. Gepirone in the treatment of major depression. J Clin Psychopharmacol 1990 Jun; 10 (3 Suppl.): 77S-85S
19. Fitton A, Benfield P. Gepirone in depression and anxiety disorders: an initial appraisal of its clinical potential. CNS Drugs 1994; 1 (5): 388-98
20. McGrath PJ, Stewart JW, Quitkin FM, et al. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. J Clin Psychopharmacol 1994 Oct; 14: 347-52
21. Feiger AD. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacol Bull 1996; 32 (4): 659-65
22. Wilcox CS, Ferguson JM, Dale JL, et al. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull 1996; 32 (3): 335-42
23. Heller AH, Beneke M, Kuemmel B, et al. Ipsapirone: evidence for efficacy in depression. Psychopharmacol Bull 1990; 26: 219-22
24. Rickels K, Derivan A, Kunz N, et al. Zalospirone in major depression: a placebo-controlled multicenter study. J Clin Psychopharmacol 1996 Jun; 16: 212-7
25. Hamilton MA. Rating for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
26. Hamilton MA. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-5
27. McNair DM, Lorr M, Droppleman LF. Profile of mood states (manual). San Diego: Educational and Industrial Testing Services, 1981
28. Rickels K, Schweizer E. The treatment of generalized anxiety disorder in patients with depressive symptomatology. J Clin Psychiatry 1993 Jan; 54 Suppl.: 20-3
29. Grof P, Joffe P, Kennedy S, et al. An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression. Int Clin Psychopharmacol 1993 Fall; 8 (3): 167-72
30. Dimitriou E. Discussant presentation: serotonin partial agonists in the treatment of depression. J Clin Psychiatry 1990 Sep; 9 Suppl. 51: 65-6
31. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand 1975; 51: 161-70
32. American Psychiatric Association. Diagnostic statistical manual of mental disorders. 3rd ed (rev). Washington, DC: American Psychiatric Association, 1987: 251-3
33. American Psychiatric Association. Diagnostic statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 432-6
34. Cohen A. The evaluation of the pharmacokinetics of buspirone and its major metabolites from a buspirone transdermal system and buspirone oral tablets in healthy volunteers: a multiple dose study. SANO Corporation, final study report: 1995 May; P512-O494
35. Sussman N. How to manage anxious patients who are depressed. J Clin Psychiatry 1993 May; Suppl. 54 (5): 8-16; discussion 17-20
36. Liebowitz MR. Antidepressants in panic disorders. Br J Psychiatry 1989; 155 Suppl. 6: 46-52
37. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology 1995; 129 (1): 1-26
38. 1A receptors and pharmacotherapy: is serotonin down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull 1994; 30 (1): 39-43
39. 1A receptors. J Clin Psychopharmacol 1990; 10 (3 Suppl.): 6s-12s
40. Modell JG. The high cost of buspirone. J Clin Psychiatry 1995 Aug; 56: 375-6
41. Bristol-Myers Squibb Co. Buspar® (buspirone Acl, USP). Physicians' desk reference. 52nd ed. Montvale, NJ: Medical Economics Co, Inc, 1998: 782
42. 1A receptor full agonist in rat cerebral cortex. Naunyn-Schmiedebergs Arch Pharmacol 1995; 352: 276-82
43. Peroutka SJ. Molecular biology of serotonin (5-HT) receptors. Synapse 1994; 18 (3): 241-60